NIH R01 · 2024
Kinome-guided Targeting of Cooperative Dependencies in BRAF Mutated Colorectal Cancer
PROJECT SUMMARY / ABSTRACT Metastatic colorectal cancer (mCRC) is the second leading cause of cancer-related death in the US. Roughly 8% of mCRCs harbor a mutation in BRAF, associated with the worst prognosis and poor response to treatment. Limitations of standard of care (SOC) therapies targeting BRAF + EGFR include a response rate of 20% and short time to cancer progression. Results of our original R01 underscore that mCRC is not dominated by individual oncogenes, rather is mediated by the concerted upregulation of multiple signaling pathways. A key discovery was a reversible SRC-relayed COX2-inflammatory program that drives resistance to BRAF + EGFR inhibition (Nature Cancer 2023).…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.